<?xml version="1.0" encoding="iso-8859-1"?>
<?xml-stylesheet title="XSL_formatting" type="text/xsl" href="cab.xsl"?>
<!DOCTYPE rss PUBLIC "-//Netscape Communications//DTD RSS 0.91//EN"
            "http://my.netscape.com/publish/formats/rss-0.91.dtd">

<rss version="0.91">
	 
	<channel>
		<title>UK-CAB news feed</title>
		 
		<link>http://www.ukcab.net</link>
		<description>UK community HIV treatment advocates network</description>
		<pubDate>Fri, 09 May 12:38:00 GMT</pubDate>
		<lastBuildDate>Fri, 09 May 12:38:00 GMT</lastBuildDate>
		 
		<language>en-gb</language>
		<copyright>UK CAB and contributors</copyright>
		<managingEditor>info@i-base.org.uk</managingEditor>
		<webMaster>info@i-base.org.uk</webMaster>
		
								<item>
		<title>
Free osteopathy for people with HIV at the British School of Osteopathy
</title>
	<link>
http://www.ukcab.net/forum/index.php?topic=148.0
</link>
	<description>
Since 2001, the British School of Osteopathy (BSO) has run a free Friday morning programme for HIV positive patients at the Chapman Clinic. In April this relocated to a brand new clinical centre at 98-118 Southwark Bridge Road (SE1 0BQ). A clinic also runs at the Ian Charleston Day Centre, Royal Free Hospital. To book treatment at the BSO Chapman Clinic call 020 7089 5360. To book treatment at the Ian Charleston Day Centre call 020 7830 2062.
</description>
	</item>
		
								<item>
		<title>
Better antibiotics for second-line PCP treatment
</title>
	<link>
http://www.ukcab.net/forum/index.php?topic=146.0
</link>
	<description>
PCP pneumonia is still a serious and present condition, especially for people diagnosed late with HIV. There is limited research on second-line treatments. A systematic review of second-line therapy PCP studies concludes clindamycin-primaquine is an alternative to intravenous pentamidine as second-line treatment for PCP in patients who fail treatment with TMP-SMX. TMP-SMX should be used as a second-line treatment for those failing first-line treatments with regimens other than TMP-SMX.
</description>
	</item>
		 		 
								<item>
		<title>
High Court ruling - asylum seekers entitled to free NHS treatment
</title>
	<link>
http://www.ukcab.net/forum/index.php?topic=133.0
</link>
	<description>
Asylum seekers refused leave to remain are entitled to free NHS care for as long as they stay in the UK, following a ruling in the High Court on 11 April by Mr Justice Mitting.
</description>
	</item>

				<item>
		<title>
BHIVA draft treatment guidelines - complete draft for comment (members only)
</title>
	<link>
http://www.ukcab.net/forum/index.php?topic=95.0
</link>
	<description>
Complete version of the new 2008 BHIVA treatment guidelines for comment. Deadline for comments: 16 May 2008.
</description>
	</item>
	
	<item>
		<title>
Meeting report - UK CAB 24
</title>
	<link>
http://www.ukcab.net/jan08/minutes.html
</link>
	<description>
BHIVA 2007 audit: treatment of naive patients. Pfizer: the drug development process. Campaigning for microbicides. Promoting PEPSE: what is the role of HIV treatment advocates? Pre-exposure prophylaxis (PrEP). Conference feedback.
	</description>
	</item>
	
		<item>
		<title>
Gay men with hepatitis C - new support group
</title>
	<link>
http://www.ukcab.net/forum/index.php?topic=85.0
</link>
	<description>
As part of its gay men's hepatitis C project, The Hepatitis C Trust is running a support group for gay men with hepatitis C, on the 3rd Wednesday of every month, commencing 19 March 2008. The group is run by gay men for gay men in response to increasing demand from those who are just diagnosed with hepatitis C, doing treatment and living with HIV and hepatitis C.
	</description>
	</item>
			
	
	<item>
		<title>
About UK CAB
</title>
		<link>
http://www.ukcab.net/about.html
</link>
	<description>
UK-CAB is a network for community HIV treatment advocates across the UK set up in May 2002. UK-CAB aims to (1) develop and strengthen a network of treatment advocates (2) provide expert training on current treatment issues and a forum for meeting with doctors, researchers and pharmaceutical companies (3) develop community representation in clinical trials and setting the standard of care.
	</description>
		</item>
	
	</channel>
	</rss>